title: PARP inhibitors.
abstract: Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.
authors.affiliation: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: Maheen
authors.initials: M
authors.lastname: Anwar
authors.affiliation: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: Hafiz Muhammad
authors.initials: HM
authors.lastname: Aslam
authors.affiliation: Final year student of Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: Shahzad
authors.initials: S
authors.lastname: Anwar
keywords: Nicotinamide; Poly (ADP-ribose) polymerases; Rucaparib